Relative Bioavailability of LY2963016 to LANTUS After Single Dose Subcutaneous Administration to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2014
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jun 2011 New trial record